To include your compound in the COVID-19 Resource Center, submit it here.

Foundation Medicine: Panoramic profiling

Novartis, Celgene early users of Foundation Medicine's tumor profiling approach

Current pharmacogenetic tests for cancer are tumor- or mutation-specific, which limits the amount of information that can be gleaned from a single test. Foundation Medicine Inc. is creating a single test designed to provide a molecular profile of a range of mutations in any tumor with a single assay. This would reduce the need for multiple tests and could identify additional treatment options for patients.

According to Gary Palmer, SVP of medical affairs and commercial development, most companion diagnostics are specific to a

Read the full 829 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers